© 2022 MJH Life Sciences and Oncology Nursing News. All rights reserved.
© 2022 MJH Life Sciences™ and Oncology Nursing News. All rights reserved.
August 20, 2022
Aditya Bardia, MD, MPH, discusses ongoing research with oral SERDs, such as elacestrant, and highlights what these agents could represent for patients with estrogen receptor–positive breast cancer.
July 17, 2022
Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.
July 03, 2022
Investigators have identified that zanubrutinib may improve the subpar health-related quality of life for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
The addition of the HER2-Vaxx vaccine to chemotherapy resulted in 41.5% reduction in the risk of death compared with chemotherapy alone among patients with gastric cancers.
May 24, 2022
Strategies to combat ethnic disparities in colorectal cancer screening are not limited to the clinic.
May 14, 2022
Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.
May 12, 2022
Patients with clear cell renal cell carcinoma experienced reduced levels of hypoxia inducible factor-2 alpha expression following treatment with ARO-HIF2.
March 30, 2022
The disparate use in telemedicine between White and Black patients warrants further exploration into compound cases, such as economic and societal factors.
March 04, 2022
A proactive, multidisciplinary approach is the best way to address belantamab mafodotin—related keratopathy in patients with multiple myeloma.
March 03, 2022
An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.